AHA Regarding the 340B Program

AHA to the Subcommittee on Oversight and Investigations Committee on Energy and Commerce regarding the 340B program.

Key Resources

Related Resources

Letter/Comment
Letter to Sec. Becerra Urging Him to Stop Six Drug Companies That Are Denying 340B Discounts
The AHA and five other health care organizations sent the attached letter to HHS Secretary Becerra urging him to stop the actions of six drug companies that…
Letter/Comment
AHA Letter to HHS Secretary Becerra on 340B Eligibility
Public
AHA urges the Department of Health and Human Services (HHS) to ensure hospitals currently participating in the 340B Drug Pricing Program continue to have…
Letter/Comment
AHA Letter Re: MedPAC’s Draft Recommendations on IME And Outpatient Drug Payments
Public
The AHA asks that commissioners consider the following issues as they recommend changes that would have a significant impact on hospitals, health systems and…
Letter/Comment
AHA Expresses Support for Legislation S. 773
Public
AHA letter to Senators, John Thune, Rob Portman, Shelley Moore Capito, Tammy Baldwin, Debbie Stabenow and Ben Cardin expressing support for legislation, S. 773.
Fact Sheets
Fact Sheet: The 340B Drug Pricing Program
Public
For more than 25 years, the 340B Drug Pricing Program has provided financial help to hospitals serving vulnerable communities to manage rising prescription…
Fact Sheets
Setting the Record Straight on 340B: Fact vs Fiction
Public
For nearly 30 years, the 340B Drug Pricing Program has provided financial help to safety-net hospitals to manage rising prescription drug costs. Section 340B…